Research
Micronutrients & recovery
SGLT-2 inhibitors reduce ectopic fat deposition, specifically liver fat (NAFLD) and visceral adipose tissue, in patients with T2DM.
SGLT-2 inhibitors not only lower blood sugar but also directly reduce fat stored in the liver and around organs. This is particularly beneficial if you have fatty liver disease, a common complication of Type 2 Diabetes.
GoodSupportsHIGH confidence
In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life.
Why this rating
Supported by specific studies (E-LIFT, Ohta et al.) showing MRI-measured fat reduction.
Source
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey‐Herng Sheu et al. · Diabetes & Metabolism Journal · 2020
narrative_reviewCited 51×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →